Teodor Nica @Millionaur: "Shake-out Week: why pre-set exits..."

Romania

Shake-out Week: why pre-set exits beat panic selling Bond yields punched through 5 % after hotter-than-expected PPI data, while Washington’s tariff volleys at Beijing reignited recession chatter. Markets wobbled, but a diversified sleeve of crypto, AI mega-caps, health-care innovators and space infrastructure still printed green. Discipline—position sizing, stop-losses and the option to copy seasoned traders—kept the receipts coming. 💵+96% $BTC 💵+57% $GOOGL (Alphabet Inc Class A) 💵+37% $MSFT (Microsoft) 💵+27% $LLY (Eli Lilly & Co) 💵+27% $RKLB (Rocket Lab Corp) ⸻ +96 % Bitcoin ($BTC) Latest news. Spot-BTC ETFs are hauling in record cash—BlackRock’s IBIT alone saw US $3.5 bn of weekly inflows, helping Bitcoin out-pace S&P-500 ETFs for 2025. Why it mattered. Institutional demand is turning digital gold into a portfolio core, adding a non-sovereign, high-beta hedge when rates and geopolitics swing. +57 % Alphabet ($GOOGL) Latest news. A lenient U.S. antitrust ruling kept Chrome and Android intact; Canaccord promptly lifted its price target to $270. Why it mattered. With the legal cloud lighter, Alphabet can keep re-investing ad-cash into Gemini AI and Cloud—defensive moat plus growth kicker in one ticker. +37 % Microsoft ($MSFT) Latest news. Microsoft’s Copilot unit struck a Harvard licensing deal to upgrade health responses, part of a push to monetise AI beyond OpenAI ties. Why it mattered. Copilot is now embedded across Windows, Office and Azure, turning AI spend into enterprise upsell and widening cloud stickiness. +27 % Eli Lilly ($LLY) Latest news. Lilly’s oral GLP-1 pill orforglipron beat Farxiga in late-stage diabetes trials, with FDA filings for obesity slated by year-end 2025. Why it mattered. A convenient weight-loss pill could extend Lilly’s dominance beyond injectable blockbuster Zepbound, giving the share an under-appreciated second engine. +27 % Rocket Lab ($RKLB) Latest news. NASA selected Rocket Lab’s reusable Neutron for upcoming VADR missions, while JAXA inked multiple Electron launches. Why it mattered. Contract momentum de-risks the move up-market and positions RKLB as a pure-play beneficiary of the small-satellite boom. ⸻ Playbook that turned volatility into cash • Trim into strength. Banking gains turns paper profit into dry powder. • Trail the rest. Stops ratchet under higher lows, so price—not ego—decides the exit. • Diversify themes. Crypto, semis, health care and space scarcely move on the same headlines, smoothing the equity curve. ⸻ Why copy trading helps most investors Keeping up with ETF flows, court rulings, Phase III read-outs and launch contracts is a full-time gig. eToro’s copy-trading lets you mirror proven managers automatically—allocation, risk caps, stop-logic—while you focus on life. It’s disciplined diversification without the screen-time tax. Bottom line: the market will keep pitching curve-balls. Lock in wins, let stops guard what’s left, and leave capital ready for the next fat pitch. ⸻ References (DYOR) JPMorgan “Liberation Day” recap on yields & tariffs AInvest: Bitcoin ETF inflow surge Canaccord price-target hike after favorable Google ruling WSJ: Microsoft Copilot healthcare push Reuters: Lilly oral GLP-1 outperforms in Phase III Rocket Lab NASA Neutron contract

5 Mentioned

BTC

GOOGL

MSFT

LLY

RKLB

Strictly Necessary Cookies

Performance Cookies

Functional Cookies

Targeting Cookies